How are Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with Non‑Obstructive Coronary Arteries (MINOCA) diagnosed and treated?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

INOCA and MINOCA Coronary Vasomotor Disorders - Diagnosis and Treatment

Pursue invasive coronary function testing (CFT) at the time of coronary angiography when non-obstructive disease is identified, as this directly identifies the underlying mechanism and enables targeted, endotype-specific therapy that improves symptoms and quality of life. 1

Diagnostic Criteria

MINOCA Definition

MINOCA requires three specific criteria 2:

  1. Meets AMI criteria per the fourth universal definition:

    • Troponin elevation with at least one value >99th percentile
    • PLUS at least one of:
      • Symptoms of myocardial ischemia
      • New ischemic ECG changes
      • Development of pathological Q waves
      • Imaging evidence of new loss of viable myocardium or regional wall motion abnormalities
      • Coronary thrombus on angiography or autopsy
  2. No obstructive CAD (≥50% stenosis) in any epicardial artery, and no overlooked obstructive disease (SCAD, embolus)

  3. Exclusion of non-ischemic mimickers (myocarditis, Takotsubo cardiomyopathy)

INOCA Definition

INOCA encompasses chronic angina or ischemia with non-obstructive coronary arteries (<50% stenosis), caused by coronary microvascular dysfunction, epicardial vasospasm, myocardial bridging, or diffuse atherosclerosis 1.

Pathophysiology - Key Mechanisms

Understanding the specific mechanism is critical because treatment differs substantially:

Atherosclerotic causes (approximately two-thirds of MINOCA) 2:

  • Plaque disruption (rupture, erosion, calcific nodules)
  • Thrombus formation with distal embolization
  • Risk factor profile similar to obstructive MI

Non-atherosclerotic causes 2:

  • Epicardial coronary vasospasm: Vascular smooth muscle hyperreactivity; >90% demonstrate vasoconstriction during acetylcholine or ergonovine testing
  • Coronary microvascular dysfunction (CMD): Found in nearly half of INOCA patients; disruption of nitric oxide, adenosine, and prostacyclin signaling 3, 4
  • SCAD: Primarily affects women (>90%); coronary intramural hematoma causing luminal obstruction; accounts for 40% of MI in women <50 years and 14-43% of pregnancy-related MI 2
  • Thromboembolism

Diagnostic Algorithm

Initial Non-Invasive Workup

When coronary angiography shows non-obstructive disease 3:

  • ECG (look for ischemic changes, Q waves)
  • Serial troponins
  • Echocardiography (regional wall motion abnormalities, LV function)
  • Coronary CT angiography (assess for diffuse atherosclerosis, myocardial bridging)

Invasive Coronary Function Testing (CFT) - Class I Recommendation

The 2024 ESC guidelines provide a Class I recommendation for CFT availability at initial coronary angiography 1. This is the critical diagnostic step that changes management.

When to perform CFT 1:

  • At time of initial coronary angiography when mechanisms are uncertain after non-invasive testing
  • In established INOCA/MINOCA patients with persistent symptoms and poor quality of life despite medical therapy

CFT Components 5, 6, 7:

  1. Intracoronary imaging (OCT or IVUS):

    • Identifies plaque disruption, SCAD, thrombus invisible to conventional angiography
    • Essential for SCAD diagnosis when angiography is equivocal
  2. Coronary flow reserve (CFR) and index of microcirculatory resistance (IMR):

    • Diagnoses coronary microvascular dysfunction
    • CFR <2.0 or elevated IMR indicates CMD
  3. Acetylcholine provocative testing:

    • Identifies epicardial and microvascular spasm
    • Positive in >50% of tested patients 7
    • Assesses endothelial dysfunction

Cardiac MRI - Non-Invasive Gold Standard

Cardiac MRI is mandatory for tissue characterization 7:

  • Confirms ischemic injury pattern
  • Excludes non-ischemic mimickers (myocarditis, Takotsubo)
  • Provides independent prognostic information
  • Reclassifies diagnosis in substantial proportion of cases

Mechanism-Based Treatment Strategy

Treatment must be guided by the specific endotype identified on CFT 1, 3. Empiric therapy without mechanism identification is inadequate.

For Plaque Disruption/Atherosclerotic Mechanisms 7:

  • Dual antiplatelet therapy (aspirin + P2Y12 inhibitor)
  • High-intensity statin therapy
  • ACE inhibitors or ARBs
  • Beta-blockers
  • Aggressive cardiovascular risk factor modification

For Epicardial Coronary Vasospasm 2, 3:

  • Calcium channel blockers (first-line; long-acting dihydropyridines or diltiazem)
  • Long-acting nitrates
  • Avoid beta-blockers (may worsen vasospasm)
  • Smoking cessation (critical - smoking is major risk factor)

For Coronary Microvascular Dysfunction 3, 8:

  • ACE inhibitors or ARBs (improve endothelial function)
  • Calcium channel blockers
  • Beta-blockers (particularly if tachycardia present)
  • Ranolazine (improves microvascular function)
  • Statins (pleiotropic endothelial effects)
  • Emerging: Rho-kinase inhibitors 8

For SCAD 2:

  • Conservative management (preferred approach)
  • Avoid anticoagulation and aggressive antiplatelet therapy
  • Beta-blockers for blood pressure control
  • Avoid percutaneous intervention unless ongoing ischemia

Combined Mechanisms

Many patients have overlapping pathophysiology 5. Tailor combination therapy based on CFT findings:

  • CMD + vasospasm: Calcium channel blocker + ACE inhibitor + ranolazine
  • Atherosclerotic + CMD: Statin + antiplatelet + ACE inhibitor + ranolazine

Critical Pitfalls to Avoid

  1. Discharging without definitive diagnosis: Approximately 50% of centers lack dedicated diagnostic pathways 9. This leads to therapeutic inertia and poor outcomes.

  2. Assuming benign prognosis: INOCA and MINOCA carry significant risk of MACE, MI, and heart failure 8. These are not benign conditions.

  3. Missing SCAD on initial angiography: Small percentage not clearly recognized; requires OCT/IVUS for intramural hematoma 2. Misclassification as MINOCA leads to inappropriate anticoagulation.

  4. Empiric therapy without mechanism identification: Only 25% of centers perform advanced invasive testing 9. CFT-guided therapy improves outcomes compared to standard care (PROMISE trial) 7.

  5. Using beta-blockers for vasospasm: May paradoxically worsen vasospasm by unopposed alpha-adrenergic vasoconstriction.

Prognostic Implications

Both INOCA and MINOCA require dedicated follow-up 9. Currently only 20% are followed in dedicated outpatient clinics, which is inadequate given:

  • Significant MACE risk comparable to obstructive CAD
  • Risk of progression to ischemic cardiomyopathy 3
  • Need for ongoing symptom management and quality of life optimization

The stratified, imaging-guided approach improves patient-centered outcomes compared to standard care, as demonstrated in the PROMISE trial 7.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.